Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cogent Biosciences (COGT) EBIT (2017 - 2026)

Cogent Biosciences' EBIT history spans 10 years, with the latest figure at -$103.6 million for Q1 2026.

  • Quarterly EBIT fell 38.27% to -$103.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$362.0 million through Mar 2026, down 25.5% year-over-year, with the annual reading at -$333.4 million for FY2025, 20.81% down from the prior year.
  • EBIT came in at -$103.6 million for Q1 2026, down from -$99.5 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$31.4 million in Q1 2022 to a low of -$103.6 million in Q1 2026.
  • The 5-year median for EBIT is -$62.4 million (2024), against an average of -$62.9 million.
  • Year-over-year, EBIT tumbled 145.45% in 2022 and then fell 10.53% in 2025.
  • Cogent Biosciences' EBIT stood at -$43.7 million in 2022, then plummeted by 33.11% to -$58.2 million in 2023, then decreased by 26.63% to -$73.7 million in 2024, then crashed by 34.94% to -$99.5 million in 2025, then dropped by 4.13% to -$103.6 million in 2026.
  • Per Business Quant, the three most recent readings for COGT's EBIT are -$103.6 million (Q1 2026), -$99.5 million (Q4 2025), and -$83.4 million (Q3 2025).